Triumeq

Triumeq

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Dolutegravir 50 mg, abacavir 600 mg, lamivudine 300 mg
Indications/Uses
Treatment of HIV infected adults & adolescents >12 yr (at least 40 kg).
Dosage/Direction for Use
Adult & adolescent (at least 40 kg) 1 tab once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Co-administration w/ dofetilide.
Special Precautions
Residual risk of HIV transmission. High risk of abacavir hypersensitivity reactions (HSR) in patients positive for HLA-B*5701 allele. Discontinue treatment if HSR is suspected. Monitor blood lipids & glucose as per established HIV treatment guidelines. Not recommended in patients w/ moderate to severe hepatic impairment unless judged necessary. Increased risk of severe & potentially fatal hepatic adverse events in patients w/ chronic hepatitis B or C treated w/ combination antiretroviral therapy. Immune reactivation syndrome; MI; osteonecrosis. Mitochondrial dysfunction in HIV negative infants exposed in utero &/or post-natally to nucleoside analogues. Opportunistic infections may continue to develop. Not recommended for patients w/ integrase inhibitor resistance. Not recommended when co-administered w/ etravirine (w/o boosted PIs), efavirenz, nevirapine, rifampicin, tipranavir/ritonavir, carbamazepine, phenytoin, phenobarb & St. John's wort; cladribine. Do not co-administer w/ polyvalent cation-containing antacids. Dose adjustment of metformin should be considered. Not recommended in patients w/ CrCl <50 mL/min. May impair ability to drive or operate machinery. Potential risk of neural tube defects w/ dolutegravir. Women of childbearing potential should undergo pregnancy testing before treatment initiation & should use effective contraception throughout treatment. Pregnancy & lactation. Elderly ≥65 yr.
Adverse Reactions
Insomnia; headache; nausea, diarrhoea; fatigue. Hypersenstivity; anorexia; abnormal dreams, depression, anxiety, nightmare, sleep disorder; dizziness, somnolence, lethargy; cough, nasal symptoms; vomiting, flatulence, abdominal pain, upper abdominal pain, abdominal distension & discomfort, GERD, dyspepsia; rash, pruritus, alopecia; arthralgia, muscle disorders (including myalgia); asthenia, fever, malaise; CPK, ALT/AST elevations.
Drug Interactions
Dolutegravir: Decreased plasma conc w/ etravirine (w/o boosted PIs); efavirenz; nevirapine; tipranavir + ritonavir; rifampicin; carbamazepine; phenobarb, phenytoin, oxcarbazepine; Mg/Al-containing antacids; Ca/Fe supplements, multivit; St. John's wort. Increased conc of dofetilide; metformin. Lamivudine: Risk for intracellular interactions w/ emtricitabine. Increased plasma conc w/ trimethoprim. Potential risk of cladribine loss of efficacy. Decreased plasma conc w/ medicines containing sorbitol & other sugar alcohols (eg, xylitol, mannitol, lactitol or maltitol).
MIMS Class
Antivirals
ATC Classification
J05AR13 - lamivudine, abacavir and dolutegravir ; Belongs to the class of antivirals for treatment of HIV infections, combinations.
Presentation/Packing
Form
Triumeq FC tab
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in